Evidence map›Paper›PMID 41537580›Full record

ArticleJournal of clinical microbiology2026

Cryptococcal antigen titers and semi-quantitative assay scores among people with HIV-associated cryptococcal antigenemia.

Tshiama M Mwamba, Nozuko P Blasich, Lindi M Coetzee, Rudzani Mashau, Nelesh P Govender

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tshiama M MwambaWits Mycology Division, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-9258-0273
Nozuko P BlasichCentre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg, South Africa.
Lindi M CoetzeeNational Priority Programmes CD4 Unit, National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0002-8981-1744
Rudzani MashauWits Mycology Division, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0003-3228-7096
Nelesh P GovenderWits Mycology Division, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-7869-9462

Funding

Phased Implementation of a Public Health Programme: Cryptococcal Screening and Treatment in South AfricaR01AI118511 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, GOVENDER, NELESH PREMAPRAGASAN · 2016 to 2020
$2.9M
CDC HHS CDC-RFA-GH15-1575National Institute of Allergy and Infectious Diseases R01AI118511NIAID NIH HHS R01 AI118511
6 · The paper itself

Abstract

While South African guidelines recommend a lumbar puncture (LP) to exclude cryptococcal meningitis (CM) among all people with a newly positive cryptococcal antigen (CrAg) test, irrespective of CM symptoms, this is not always feasible. High blood CrAg lateral flow assay (LFA) titers are associated with concurrent CM and increased mortality. Single-strip CrAg semi-quantitative (SQ) tests could risk-stratify people with antigenemia. Consecutive fresh LFA-positive remnant plasma samples from a CD4 laboratory network collected between April and July 2021 were retested. We described LFA titers, CrAgSQ scores, and the proportion with cerebrospinal fluid (CSF) collected 28 days before or after a positive CrAg screening test. Of 2,240 re-tested plasma samples from unique patients, 2,166 (97%) were confirmed LFA-positive. The median LFA titer was 640 (IQR, 40-5,120), 63% (1,354/2,166) had a titer of ≥160, and 52% (1,124/2,166) had SQ scores of ≥3+. Only 31% (662/2,166) had a CSF sample collected 28 days before or after a CrAg LFA-positive test; 60% (398/662) had confirmed CM. More than half of the people with cryptococcal antigenemia had a blood CrAg titer of ≥160 or a CrAgSQ score of ≥3+, both previously shown to confer a high risk of concurrent CM. Of 3 in 10 who had an LP, most had CM, suggesting that meningitis symptoms prompted LP. Healthcare worker support/training is required to improve adherence to the universal LP recommendation. When immediate LP is not feasible, blood CrAgSQ testing can rapidly identify people at the highest risk of CM who require urgent referral for LP. IMPORTANCE: A majority of patients with HIV-associated cryptococcal antigenemia identified through a large screening program in South Africa had high cryptococcal antigen titers and thus an elevated risk of concurrent meningitis and death. Despite this, a relatively small proportion had a lumbar puncture to definitively exclude meningitis. Routine CrAg semi-quantification can help to stratify patients at higher risk for meningitis and guide clinicians' management, but performing a full range of titers for all CrAg-positive blood samples increases costs and is labor-intensive. An alternative approach is to use a single test strip, which yields a semi-quantitative score.

Indexed as

AIDS-Related Opportunistic InfectionsAntigens, FungalCryptococcosisCryptococcusHIV InfectionsMeningitis, CryptococcalAdultFemaleHumansMaleSouth AfricaSpinal PunctureAntigens, Fungalcryptococcal antigencryptococcal antigenemiacryptococcal meningitisCryptococcuslateral flow assaysemi-quantitativeSouth Africa

Identifiers

PMID41537580
PMCPMC12892947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.